Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Philogen SpA's enterprise value is €563.4 Mil.
Philogen SpA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €264.7 Mil. Therefore, Philogen SpA's EV-to-EBITDA for today is 2.13.
The historical rank and industry rank for Philogen SpA's EV-to-EBITDA or its related term are showing as below:
MIL:PHIL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -586.8 Med: -43.14 Max: 22.1
Current: 2.13
During the past 6 years, the highest EV-to-EBITDA of Philogen SpA was 22.10. The lowest was -586.80. And the median was -43.14.
MIL:PHIL's EV-to-EBITDA is ranked better than 72.28% of 404
companies
in the Biotechnology industry
Industry Median: 11.82
vs MIL:PHIL: 2.13
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Philogen SpA (MIL:PHIL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Philogen SpA's PE Ratio (TTM) for today is calculated as:
Philogen SpA's share price for today is €23.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Philogen SpA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €5.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Philogen SpA's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:PHIL vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Philogen SpA's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Philogen SpA EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Philogen SpA's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Philogen SpA's EV-to-EBITDA falls into.
Philogen SpA's current Enterprise Value is €563.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Philogen SpA's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €264.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Philogen SpA (MIL:PHIL) has a EV-to-EBITDA of 2.13 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Philogen SpA. According to the industry distribution chart, Philogen SpA ranks #112 out of 404 companies in the Biotechnology industry, placing it in the top 27.7%.
Is Philogen SpA's EV-to-EBITDA too high?
Philogen SpA's current EV-to-EBITDA is 2.13. The Biotechnology industry median EV-to-EBITDA is 11.82. Philogen SpA's value of 2.13 is 82% below this industry median. Based on the distribution chart, Philogen SpA ranks #112 out of 404 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Philogen SpA has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Philogen SpA's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Philogen SpA ranks #112 out of 404 companies for EV-to-EBITDA. This puts Philogen SpA in the upper half of its industry. The industry median EV-to-EBITDA is 11.82. Philogen SpA's value of 2.13 is 82% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.82, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Philogen SpA's current EV-to-EBITDA of 2.13 is 82% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Philogen SpA. For the Biotechnology industry, the median EV-to-EBITDA is 11.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Philogen SpA's current EV-to-EBITDA is 2.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Philogen SpA stock overvalued right now?
Based on GuruFocus' analysis, Philogen SpA (MIL:PHIL) is currently considered Possible Value Trap. The stock's GF Value™ is €230.73, compared to a current price of €23.15 — trading 90% below its estimated fair value. The current EV-to-EBITDA is 2.13 and 82% below the Biotechnology industry median of 11.82. Philogen SpA's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Philogen SpA (MIL:PHIL), the current EV-to-EBITDA is 2.13 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Philogen SpA (MIL:PHIL) Overvalued in 2026?
Based on GuruFocus' analysis, Philogen SpA stock appears to be undervalued.
The current stock price of €23.15 is trading 90% below its estimated GF Value™ of €230.73.
GuruFocus considers Philogen SpA to be Possible Value Trap.
Key valuation signals for MIL:PHIL:
EV-to-EBITDA: 2.13
GF Value™: €230.73 vs. price of €23.15 (90% below fair value)
Industry Position: 82% below the Biotechnology median (#112 of 404)
No single metric tells the full story. See the MIL:PHIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Philogen SpA is a biotechnology company engaged in the research and development of antibody-based therapeutics for the treatment of cancer and chronic inflammatory diseases. The company's pipeline includes products such as Nidlegy, Fibromun, Darleukin, and Dekavil, targeting oncology and other serious conditions. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
59GF Score
Get the complete analysis for MIL:PHIL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHIL has been successfully added to your 
